Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population‐Based IBDSL Cohort. (March 2018)

• Record Type: Journal Article
• Authors: Jeuring, Steven F G; Biemans, Vince B C; van den Heuvel, Tim R A; Zeegers, Maurice P; Hameeteman, Wim H; Romberg‐Camps, Mariëlle J L; Oostenbrug, Liekele E; Masclee, Ad A M; Jonkers, Daisy M A E; Pierik, Marieke J
• Is Part Of: American journal of gastroenterology. Volume 113:Number 3(2018)
• Publication Date: 2018-03
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Gastrointestinal Diseases -- Periodicals; Electronic journals; Periodicals; 616.33
• DOI: 10.1038/ajg.2017.482
• Languages: English
• ISSNs: 0002-9270

Abstract

Abstract : OBJECTIVES: Corticosteroid‐free remission is an emerging treatment goal in the management of inflammatory bowel disease (IBD). In the population‐based Inflammatory Bowel Disease South Limburg cohort, we studied temporal changes in corticosteroid use and assessed the corticosteroid‐sparing effects of immunomodulators and biologicals in real life. METHODS: In total, 2, 823 newly diagnosed patients with Crohn's disease (CD) or ulcerative colitis (UC) were included. Corticosteroid exposure and cumulative days of use were compared between patients diagnosed in 1991–1998 (CD: n =316, UC: n =539), 1999–2005 (CD: n =387, UC: n =527), and 2006–2011 (CD: n =459, UC: n =595). Second, the corticosteroid‐sparing effects of immunomodulators and biologicals were assessed. RESULTS: Over time, the corticosteroid exposure rate was stable (54.0% in CD and 31.4% in UC), even as the cumulative corticosteroid use in the first disease year (CD: 83 days (interquartile range (IQR) 35–189), UC: 62 days (IQR 0–137)). On the long‐term, a gradual decrease in cumulative corticosteroid use was seen in CD (era '91–'98: 366 days (IQR 107–841), era '06–'11: 120 days (IQR 72–211), P <0.01), whereas in UC an initial decrease was observed (era '91–'98: 184 days (IQR 86–443), era '99–'05: 166 days (IQR 74–281), P =0.03), and stabilization thereafter. Immunomodulator and biological users had a lower risk of requiring corticosteroids than matched controls in CD only (33.6% vs. 49.9%, P <0.01, and 25.7% vs. 38.2%, P =0.04, respectively). CONCLUSIONS: In a real‐world setting, more recently diagnosed IBD patients used lower amounts of corticosteroids as of the second year of disease. For CD, a significant association was found with the use of immunomodulators and biologicals. These conclusions support the increasing use of these treatment modalities.